NCT06507618View on ClinicalTrials.gov

Pre-Operative Window of ET to Inform RT Decisions (POWER II)

PHASE3RecruitingINTERVENTIONAL
Enrollment

354

Participants

Timeline

Start Date

July 19, 2024

Primary Completion Date

June 30, 2029

Study Completion Date

March 1, 2034

Conditions
Breast Cancer Female
Interventions
DRUG

Tamoxifen, Letrozole, Anastrozole, or Exemestane

Choice and dose of neoadjuvant endocrine therapy at the discretion of the treating medical oncologist.

Trial Locations (3)

22031

RECRUITING

INOVA Schar Cancer, Fairfax

22903

RECRUITING

University of Virginia, Charlottesville

23298

RECRUITING

Virginia Commonwealth University, Richmond

All Listed Sponsors
lead

University of Virginia

OTHER